CURRICULUM VITAE (June, 2020)

GEORGE BLANCK

Department of Molecular Medicine
University of South Florida
Morsani College of Medicine
12901 Bruce B. Downs Bd. MDC 7
Tampa, Florida 33612
(813) 974-9585
gblanck@usf.edu

EDUCATION

1984 Doctor of Philosophy, Department of Biological Sciences, Columbia University, New York, New York. Advisor: Dr. Robert Pollack. Dissertation title: Analysis of integrated viral DNA in SV40 transformed mouse cells.

1979 Master of Arts, Department of Biological Sciences, Columbia University.

1978 Bachelor of Arts, Faculty of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania (Major: Biology).

GRADUATE TEACHING EXPERIENCE

1978-80 Teaching assistant for introductory molecular biology and genetics courses.

POSTDOCTORAL EXPERIENCE

1989 INSERM fellowship, laboratory of Dr. Dominique Charron, Universite de Paris VI, Institut des Cordeliers, Paris, France.

1984-88 Multiple Sclerosis/NIH fellowships, laboratory of Dr. Jack Strominger, Department of Biochemistry and Molecular Biology, Harvard University, Cambridge, Massachusetts.

1983-84 Postdoctoral research associate in the laboratory of Dr. Robert Pollack, Department of Biological Sciences, Columbia University, New York, New York.

PROFESSIONAL EXPERIENCE

2016- Visiting scholar, Scripps, Florida (USF sabbatical)

1990- **Assistant/Associate (1995-)/Full (2002) Professor, Department of Molecular Medicine (formerly Biochemistry and Molecular Biology), University of South Florida, Morsani College of Medicine, Tampa, Florida (primary appointment).**

2000- Associate Professor, Department of Microbiology and Immunology, University of South Florida, Morsani College of Medicine, Tampa, Florida (now part of the Molecular Medicine Department)

1999 Visiting Scholar, Vanderbilt University School of Medicine, Nashville, Tennessee (USF sabbatical).

1999- Associate Professor, Department of Pathology, University of South Florida, Morsani College of Medicine, Tampa, Florida (courtesy appt).

1993- Member, Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida (courtesy appt).

1991-2002 Member, Institute for Biomolecular Science, University of South Florida, Tampa, Florida (now defunct).

PUBLICATIONS

Starting with recent. (1-113)

1. Zaman S, Chobrutskiy BI, Patel JS, Diviney A, Tu YN, Tong WL, Gill T, Blanck G. Antiviral T Cell Receptor Complementarity Determining Region-3 Sequences Are Associated with a Worse Cancer Outcome: A Pancancer Analysis. Viral Immunol. 2020. doi: 10.1089/vim.2019.0156. PubMed PMID: 32315578.
2. Tu YN, Tong WL, Callahan BM, Chobrutskiy BI, Blanck G. B-cell Receptor Recombinations in Lung Adenocarcinoma Exome Files Correlate With a Higher Overall Survival Rate. Anticancer research. 2020;40(4):2043-51. doi: 10.21873/anticanres.14161. PubMed PMID: 32234895.
3. Chobrutskiy BI, Yeagley M, Diviney A, Zaman S, Gozlan EC, Tipping P, Koohestani DM, Roca AM, Blanck G. A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: Multi-cancer analyses of associated survival rates. Immunology. 2019. doi: 10.1111/imm.13165. PubMed PMID: 31821535.
4. Chobrutskiy BI, Yeagley M, Tipping P, Zaman S, Diviney A, Patel DN, Falasiri S, Uversky VN, Blanck G. Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma. Oncogene. 2019. doi: 10.1038/s41388-019-1101-2. PubMed PMID: 31740784.
5. Arturo JF, Chobrutskiy BI, Yeagley M, Patel DN, Falasiri S, Patel JS, Blanck G. Electrostatic complementarity of B-cell receptor CDR3s and TP53-mutant amino acids in breast cancer is associated with increased disease-free survival rates. Cell Mol Immunol. 2019. doi: 10.1038/s41423-019-0328-8. PubMed PMID: 31729463.
6. Pakasticali N, Gill T, Chobrutskiy BI, Tong WL, Ramsamooj M, Blanck G. TRAV gene segments further away from the TRAJ gene segment cluster appear more commonly in human tumor and blood samples. Molecular immunology. 2019;116:174-9. doi: 10.1016/j.molimm.2019.10.010. PubMed PMID: 31704500.
7. Clark KR, Tong WL, Callahan BM, Yavorski JM, Tu YN, Blanck G. TRB-J1 usage, in combination with the HLA-A*01:01 allele, represents an apparent survival advantage for uterine corpus endometrial carcinoma: Comparisons with microscopic assessments of lymphocyte infiltrates. Int J Immunogenet 2019; 46:31-7.

8. Roca AM, Chobrutskiy BI, Callahan BM, Blanck G. T-cell receptor V and J usage paired with specific HLA alleles associates with distinct cervical cancer survival rates. Hum Immunol 2019.
9. Patel JS, Callahan BM, Chobrutskiy BI, Blanck G. Matrix-metalloprotease resistant mucin-16 (MUC16) peptide mutants represent a worse lung adenocarcinoma outcome. Proteomics Clin Appl 2019:e1800155.
10. Zaman S, Chobrutskiy BI, Patel JS, Callahan BM, Mihyu MM, Diviney A, et al. Potential MMP2-mediated availability of HLA binding, mutant ECM peptides reflects better melanoma survival rates and greater T-cell infiltrates. Lab Invest 2019.
11. Diviney A, Chobrutskiy BI, Zaman S, Blanck G. An age-based, RNA expression paradigm for survival biomarker identification for pediatric neuroblastoma and acute lymphoblastic leukemia. Cancer Cell Int 2019; 19:73.
12. Chobrutskiy BI, Zaman S, Diviney A, Mihyu MM, Blanck G. T-cell receptor-alpha CDR3 domain chemical features correlate with survival rates in bladder cancer. J Cancer Res Clin Oncol 2019; 145:615-23.
13. Zaman S, Chobrutskiy BI, Sikaria D, Blanck G. MAPT (Tau) expression is a biomarker for an increased rate of survival for lowgrade glioma. Oncol Rep 2019; 41:1359-66.
14. Zaman S, Chobrutskiy BI, Patel JS, Callahan BM, Tong WL, Mihyu MM, et al. MMP7 sensitivity of mutant ECM proteins: An indicator of melanoma survival rates and T-cell infiltration. Clin Biochem 2019; 63:85-91.
15. Sikaria D, Tu YN, Fisler DA, Mauro JA, Blanck G. Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma. J Cancer Res Clin Oncol 2018.
16. Callahan BM, Tong WL, Blanck G. T cell receptor-beta J usage, in combination with particular HLA class II alleles, correlates with better cancer survival rates. Immunol Res 2018; 66:219-23.
17. Callahan BM, Patel JS, Fawcett TJ, Blanck G. Cytoskeleton and ECM tumor mutant peptides: Increased protease sensitivities and potential consequences for the HLA class I mutant epitope reservoir. Int J Cancer 2018; 142:988-98.
18. Callahan BM, Yavorski JM, Tu YN, Tong WL, Kinskey JC, Clark KR, et al. T-cell receptor-beta V and J usage, in combination with particular HLA class I and class II alleles, correlates with cancer survival patterns. Cancer Immunol Immunother 2018; 67:885-92.
19. Kinskey JC, Tu YN, Tong WL, Yavorski JM, Blanck G. Recovery of Immunoglobulin VJ Recombinations from Pancreatic Cancer Exome Files Strongly Correlates with Reduced Survival. Cancer Microenviron 2018; 11:51-9.
20. Mai AT, Tong WL, Tu YN, Blanck G. TcR-alpha recombinations in renal cell carcinoma exome files correlate with an intermediate level of T-cell exhaustion biomarkers. Int Immunol 2018; 30:35-40.
21. Tu YN, Tong WL, Yavorski JM, Blanck G. Immunogenomics: A Negative Prostate Cancer Outcome Associated with TcR-gamma/delta Recombinations. Cancer Microenviron 2018; 11:41-9.
22. Falasiri S, Rahman T, Tu YN, Fawcett TJ, Blanck G. Germline cytoskeletal and extra-cellular matrix-related single nucleotide variations associated with distinct cancer survival rates. Gene 2018; 669:91-8.
23. Fisler DA, Sikaria D, Yavorski JM, Tu YN, Blanck G. Elucidating feed-forward apoptosis signatures in breast cancer datasets: Higher FOS expression associated with a better outcome. Oncol Lett 2018; 16:2757-63.
24. Tong WL, Callahan BM, Tu YN, Zaman S, Chobrutskiy BI, Blanck G. Immune receptor recombinations from breast cancer exome files, independently and in combination

with specific HLA alleles, correlate with better survival rates. Breast Cancer Res Treat 2018.
25. Zaman S, Chobrutskiy BI, Patel JS, Callahan BM, Tong WL, Blanck G. Mutant cytoskeletal and ECM peptides sensitive to the ST14 protease are associated with a worse outcome for glioblastoma multiforme. Biochem Biophys Res Commun 2018; 503:2218-25.
26. Chobrutskiy BI, Zaman S, Tong WL, Diviney A, Blanck G. Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade. J Neurooncol 2018; 140:697-704.
27. Zaman S, Chobrutskiy BI, Blanck G. MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma. Cell Cycle 2018; 17:2474-83.
28. Mauro JA, Yavorski JM, Blanck G. Stratifying melanoma and breast cancer TCGA datasets on the basis of the CNV of transcription factor binding sites common to proliferation- and apoptosis-effector genes. Gene 2017.
29. Samy MD, Tong WL, Yavorski JM, Sexton WJ, Blanck G. T cell receptor gene recombinations in human tumor specimen exome files: detection of T cell receptor-beta VDJ recombinations associates with a favorable oncologic outcome for bladder cancer. Cancer Immunol Immunother 2017; 66:403-10.
30. Stoll RJ, Thompson GR, Samy MD, Blanck G. De novo, systemic, deleterious amino acid substitutions are common in large cytoskeleton-related protein coding regions. Biomed Rep 2017; 6:211-6.
31. Uversky VN, Tu YN, Nwogu O, Butler SN, Ramsamooj M, Blanck G. High-level intrinsic disorder explains the universality of CLIP binding to diverse MHC class II variants. Cell Mol Immunol 2017.
32. Yavorski JM, Stoll RJ, Samy MD, Mauro JA, Blanck G. Identification of Sets of Cytoskeletal Related and Adhesion-related Coding Region Mutations in the TCGA Melanoma Dataset that Correlate with a Negative Outcome. Curr Genomics 2017; 18:287-97.
33. Segarra DT, Yavorski JM, Blanck G. Protected cytoskeletal-related proteins: Towards a resolution of contradictions regarding the role of the cytoskeleton in cancer. Biomed Rep 2017; 7:163-8.
34. Tong WL, Tu YN, Samy MD, Sexton WJ, Blanck G. Identification of immunoglobulin V(D)J recombinations in solid tumor specimen exome files: Evidence for high level B-cell infiltrates in breast cancer. Hum Vaccin Immunother 2017; 13:501-6.
35. Clark NM, Garcia Galindo CA, Patel VK, Parry ML, Stoll RJ, Yavorski JM, et al. The human, F-actin-based cytoskeleton as a mutagen sensor. Cancer Cell Int 2017; 17:121.
36. Tu YN, Tong WL, Fawcett TJ, Blanck G. Lung tumor exome files with T-cell receptor recombinations: a mouse model of T-cell infiltrates reflecting mutation burdens. Lab Invest 2017; 97:1516-20.
37. Tu YN, Tong WL, Samy MD, Yavorski JM, Kim M, Blanck G. Assessing microenvironment immunogenicity using tumor specimen exomes: Co-detection of TcR-alpha/beta V(D)J recombinations correlates with PD-1 expression. Int J Cancer 2017; 140:2568-76.
38. Yavorski JM, Blanck G. MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development. Mol Clin Oncol 2017; 7:1119-21.
39. Butler SN, Blanck G. Immunoscoring by correlating MHC class II and TCR expression: high level immune functions represented by the KIRP dataset of TCGA. Cell Tissue Res 2016; 363:491-6.

40. Parry ML, Blanck G. Flat cells come full sphere: Are mutant cytoskeletal-related proteins oncoprotein-monsters or useful immunogens? Hum Vaccin Immunother 2016; 12:120-3.
41. Yavorski JM, Blanck G. TCGA: Increased oncoprotein coding region mutations correlate with a greater expression of apoptosis-effector genes and a positive outcome for stomach adenocarcinoma. Cell Cycle 2016:1-7.
42. Sait S, Fawcett T, Blanck G. Overlap of the cancer genome atlas and the immune epitope database. Oncol Lett 2016; 12:2982-4.
43. Samy MD, Yavorski JM, Mauro JA, Blanck G. Impact of SNPs on CpG Islands in the MYC and HRAS oncogenes and in a wide variety of tumor suppressor genes: A multi-cancer approach. Cell Cycle 2016; 15:1572-8.
44. Gill TR, Samy MD, Butler SN, Mauro JA, Sexton WJ, Blanck G. Detection of Productively Rearranged TcR-alpha V-J Sequences in TCGA Exome Files: Implications for Tumor Immunoscoring and Recovery of Antitumor T-cells. Cancer Inform 2016; 15:23-8.
45. Yavorski JM, Blanck G. Smoking correlates with increased cytoskeletal protein-related coding region mutations in the lung and head and neck datasets of the cancer genome atlas. Physiol Rep 2016; 4.
46. Parry ML, Ramsamooj M, Blanck G. Big genes are big mutagen targets: A connection to cancerous, spherical cells? Cancer Lett 2015; 356:479-82.
47. Mauro JA, Butler SN, Ramsamooj M, Blanck G. Copy number loss or silencing of apoptosis-effector genes in cancer. Gene 2015; 554:50-7.
48. Frangione ML, Lockhart JH, Morton DT, Pava LM, Blanck G. Anticipating designer drug-resistant cancer cells. Drug Discov Today 2015.
49. Garcia M, Mauro JA, Ramsamooj M, Blanck G. Tumor suppressor genes are larger than apoptosis-effector genes and have more regions of active chromatin: Connection to a stochastic paradigm for sequential gene expression programs. Cell Cycle 2015; 14:2494-500.
50. Blanck G. Letter to the Editor: Giant proteins and cancer chemotherapy cardiotoxicity. Am J Physiol Heart Circ Physiol 2015; 309:H718.
51. Lloyd MC, Szekeres K, Brown JS, Blanck G. Class II transactivator expression in melanoma cells facilitates T-cell engulfment. Anticancer Res 2015; 35:25-9.
52. Blazekovic F, Odukoya D, Butler SN, Mauro JA, Ramsamooj M, Puleo E, et al. HLA-DR peptide occupancy can be regulated with a wide variety of small molecules. Hum Vaccin Immunother 2015:0.
53. Fawcett TJ, Parry ML, Blanck G. A Novel Approach to Evaluating Cancer Driver Gene Mutation Densities: Cytoskeleton-related Gene Candidates. Cancer Genomics Proteomics 2015; 12:283-90.
54. Mauro JA, Blanck G. Functionally distinct gene classes as bigger or smaller transcription factor traps: a possible stochastic component to sequential gene expression programs in cancer. Gene 2014; 536:398-406.
55. Lloyd MC, Burke N, Kalantarpour F, Niesen MI, Hall A, Pennypacker K, et al. Quantitative Morphological and Molecular Pathology of the Human Thymus Correlate with Infant Cause of Death. Technol Innov 2014; 16:55-62.
56. Ford SA, Blanck G. Signal persistence and amplification in cancer development and possible, related opportunities for novel therapies. Biochim Biophys Acta 2014; 1855:18-23.
57. Szekeres K, Koul R, Mauro J, Lloyd M, Johnson J, Blanck G. An Oct-1-based, feed-forward mechanism of apoptosis inhibited by co-culture with Raji B-cells: towards a model of the cancer cell/B-cell microenvironment. Exp Mol Pathol 2014; 97:585-9.

58. Blanck G. The rise of the biomedical sciences master's program at U.S. medical colleges. Teach Learn Med 2014; 26:409-11.
59. Pillai S, Szekeres K, Lawrence NJ, Chellappan SP, Blanck G. Regulation of interlocking gene regulatory network subcircuits by a small molecule inhibitor of retinoblastoma protein (RB) phosphorylation: cancer cell expression of HLA-DR. Gene 2013; 512:403-7.
60. Blanck G. The future of cancer research: Prevention, screening, vaccines, and tumor-specific drug combos. Hum Vaccin Immunother 2013; 10.
61. Cronin K, Escobar H, Szekeres K, Reyes-Vargas E, Rockwood AL, Lloyd MC, et al. Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors. Hum Vaccin Immunother 2013; 9:784-9.
62. Pava LM, Morton DT, Chen R, Blanck G. Unifying the genomics-based classes of cancer fusion gene partners: large cancer fusion genes are evolutionarily conserved. Cancer Genomics Proteomics 2012; 9:389-95.
63. Long K, Abuelenen T, Pava L, Bastille M, Blanck G. Size matters: sequential mutations in tumorigenesis may reflect the stochastic effect of mutagen target sizes. Genes Cancer 2011; 2:927-31.
64. Mohapatra S, Park SJ, Boyapalle S, Pastey MK, Graham BS, Blanck G. Human respiratory syncytial virus reduces the number of cells in S-phase and increases GADD153 expression in HEp-2 cells. Acta Virol 2009; 53:207-11.
65. Narsing S, Jelsovsky Z, Mbah A, Blanck G. Genes that contribute to cancer fusion genes are large and evolutionarily conserved. Cancer Genet Cytogenet 2009; 191:78-84.
66. Coppola D, Parikh V, Boulware D, Blanck G. Substantially reduced expression of PIAS1 is associated with colon cancer development. J Cancer Res Clin Oncol 2009; 135:1287-91.
67. Niesen MI, Osborne AR, Lagor WR, Zhang H, Kazemfar K, Ness GC, et al. Technological advances in the study of HLA-DRA promoter regulation: extending the functions of CIITA, Oct-1, Rb, and RFX. Acta Biochim Biophys Sin (Shanghai) 2009; 41:198-205.
68. Niesen MI, Blanck G. Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor. Biol Pharm Bull 2009; 32:480-2.
69. Kazemfar K, Chen R, Nicholson K, Coppola D, Zhou JM, Chen X, et al. Combined IL-8 and TGF-beta blockade efficiently prevents neutrophil infiltrates into an A549-cell tumor. Immunol Lett 2009; 122:26-9.
70. Xu L, Niesen MI, Blanck G. Linkage of a tumor immune function and cell cycle de-regulation via a gene regulatory network subcircuit. Mol Immunol 2009; 46:569-75.
71. Spies T, Bresnahan M, Bahram S, Arnold D, Blanck G, Mellins E, et al. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. 1990. J Immunol 2008; 180:2737-40.
72. Palubin KM, Goodwin BL, Niesen MI, Le EA, Osborne AR, Blanck G. A direct mechanistic link between growth control and a tumor cell immune function: increased interleukin-8 secretion accounts for elimination of Oct-1 antisense transformants from scid mice. Anticancer Res 2006; 26:1733-8.
73. Osborne AR, Zhang H, Blanck G. Oct-1 DNA binding activity unresponsive to retinoblastoma protein expression prevents MHC class II induction in a non-small cell lung carcinoma cell line. Mol Immunol 2006; 43:710-6.
74. Le E, Zhang H, Blanck G. CIITA transformation rescues the apoptotic function of MHC class II in melanoma cells. Anticancer Res 2005; 25:3889-92.

75. Niesen MI, Osborne AR, Yang H, Rastogi S, Chellappan S, Cheng JQ, et al. Activation of a methylated promoter mediated by a sequence-specific DNA-binding protein, RFX. J Biol Chem 2005; 280:38914-22.
76. Osborne AR, Zhang H, Fejer G, Palubin KM, Niesen MI, Blanck G. Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells: an Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter. J Biol Chem 2004; 279:28911-9.
77. Blanck G. Mutations and regulatory anomalies effecting tumor cell immune functions. Cancer Immunol Immunother 2004; 53:1-16.
78. Eason DD, LeBron C, Coppola D, Moscinski LC, Livingston S, Sutton ET, et al. Development of CD30+ lymphoproliferative disease in mice lacking interferon regulatory factor-1. Oncogene 2003; 22:6166-76.
79. Xi H, Blanck G. The IRF-2 DNA binding domain facilitates the activation of the class II transactivator (CIITA) type IV promoter by IRF-1. Mol Immunol 2003; 39:677-84.
80. Blanck G. Components of the IFN-gamma signaling pathway in tumorigenesis. Arch Immunol Ther Exp (Warsz) 2002; 50:151-8.
81. Osborne A, Zhang H, Yang WM, Seto E, Blanck G. Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation. Mol Cell Biol 2001; 21:6495-506.
82. Eason DD, Coppola D, Livingston S, Shepherd AT, Blanck G. Loss of MHC class II inducibility in hyperplastic tissue in Rb-defective mice. Cancer Lett 2001; 171:209-14.
83. Xi H, Goodwin B, Shepherd AT, Blanck G. Impaired class II transactivator expression in mice lacking interferon regulatory factor-2. Oncogene 2001; 20:4219-27.
84. Goodwin BL, Xi H, Tejiram R, Eason DD, Ghosh N, Wright KL, et al. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth Differ 2001; 12:327-35.
85. Zhang H, Wei S, Sun J, Coppola D, Zhong B, Wu GD, et al. Retinoblastoma protein activation of interleukin 8 expression inhibits tumor cell survival in nude mice. Cell Growth Differ 2000; 11:635-9.
86. Xi H, Blanck G. Interferon regulatory factor-2 point mutations in human pancreatic tumors. Int J Cancer 2000; 87:803-8.
87. Blanck G. HLA class II expression in human tumor lines. Microbes Infect 1999; 1:913-8.
88. Xi H, Eason DD, Ghosh D, Dovhey S, Wright KL, Blanck G. Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2. Oncogene 1999; 18:5889-903.
89. Zhang H, Shepherd AT, Eason DD, Wei S, Diaz JI, Djeu JY, et al. Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Cell Growth Differ 1999; 10:457-65.
90. Eason DD, Shepherd AT, Blanck G. Interferon regulatory factor 1 tryptophan 11 to arginine point mutation abolishes DNA binding. Biochim Biophys Acta 1999; 1446:140-4.
91. Osborne A, Tschickardt M, Blanck G. Retinoblastoma protein expression facilitates chromatin remodeling at the HLA-DRA promoter. Nucleic Acids Res 1997; 25:5095-102.
92. Lu Y, Tschickardt ME, Schmidt BJ, Blanck G. IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes. Immunol Cell Biol 1997; 75:325-32.

93. Schmidt B, Carter SS, Berry DE, Blanck G. Vitamin D3 reduces the apoptotic effect of IFN-gamma but does not facilitate HLA class II inducibility in RB-defective cells. Cancer Lett 1996; 110:169-76.
94. Lu Y, Boss JM, Hu SX, Xu HJ, Blanck G. Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-gamma inducibility in non-small cell lung carcinoma cells. Lack of surface class II expression associated with a specific defect in HLA-DRA induction. J Immunol 1996; 156:2495-502.
95. Berry DE, Lu Y, Schmidt B, Fallon PG, O'Connell C, Hu SX, et al. Retinoblastoma protein inhibits IFN-gamma induced apoptosis. Oncogene 1996; 12:1809-19.
96. Tschickardt ME, Lu Y, Jacim M, Ussery GD, Steimle V, Mach B, et al. RB and a novel E2F-1 binding protein in MHC class II deficient B-cell lines and normal IFN-gamma induction of the class IL transactivator CIITA in class II non-inducible RB-defective tumor lines. Int J Cancer 1995; 62:461-5.
97. Lu Y, Ussery GD, Muncaster MM, Gallie BL, Blanck G. Evidence for retinoblastoma protein (RB) dependent and independent IFN-gamma responses: RB coordinately rescues IFN-gamma induction of MHC class II gene transcription in noninducible breast carcinoma cells. Oncogene 1994; 9:1015-9.
98. Lu Y, Ussery GD, Jacim M, Tschickardt M, Boss JM, Blanck G. Retinoblastoma protein regulation of surface CD74 (invariant chain) expression in breast carcinoma cells. Mol Immunol 1994; 31:1365-8.
99. Blanck G, Lok M, Kok K, Downie E, Korn JH, Strominger JL. Gamma-interferon induction of HLA class II mRNAs in dermal fibroblasts studied by RNAse protection analysis. Hum Immunol 1990; 29:150-6.
100. Blanck G, Strominger JL. Cosmid clones in the HLA-DZ and -DP subregions. Hum Immunol 1990; 27:265-8.
101. Spies T, Bresnahan M, Bahram S, Arnold D, Blanck G, Mellins E, et al. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 1990; 348:744-7.
102. Spies T, Blanck G, Bresnahan M, Sands J, Strominger JL. A new cluster of genes within the human major histocompatibility complex. Science 1989; 243:214-7.
103. Blanck G, Strominger JL. Molecular organization of the DQ subregion (DO-DX-DV-DQ) of the human MHC and its evolutionary implications. J Immunol 1988; 141:1734-7.
104. Blanck G, Li D, Pomert E, Pollack R, Chen S. Multiple insertions and tandem repeats of origin-minus simian virus 40 DNA in transformed rat and mouse cells. J Virol 1988; 62:1520-3.
105. Levitt A, Chen S, Blanck G, George D, Pollack RE. Two integrated partial repeats of simian virus 40 together code for a super-T antigen. Mol Cell Biol 1985; 5:742-50.
106. Nicholson NB, Chen S, Blanck G, Pollack R. SV40 transformation of Swiss 3T3 cells can cause a stable reduction in the calcium requirement for growth. J Cell Biol 1984; 99:2314-21.
107. Chen S, Blanck G, Pollack R. Reacquisition of a functional early region by a mouse transformant containing only defective simian virus 40 DNA. Mol Cell Biol 1984; 4:666-70.
108. Blanck G, Chen S, Pollack R. DNase I sensitivity of integrated simian virus 40 DNA. Mol Cell Biol 1984; 4:559-62.
109. Lewis ED, Chen S, Kumar A, Blanck G, Pollack RE, Manley JL. A frameshift mutation affecting the carboxyl terminus of the simian virus 40 large tumor antigen results in a replication- and transformation-defective virus. Proc Natl Acad Sci U S A 1983; 80:7065-9.

110. Chen S, Grass DS, Blanck G, Hoganson N, Manley JL, Pollack RE. A functional simian virus 40 origin of replication is required for the generation of a super T antigen with a molecular weight of 100,000 in transformed mouse cells. J Virol 1983; 48:492-502.
111. Chen S, Blanck G, Pollack RE. Pre-crisis mouse cells show strain-specific covariation in the amount of 54-kilodalton phosphoprotein and in susceptibility to transformation by simian virus 40. Proc Natl Acad Sci U S A 1983; 80:5670-4.
112. Blanck G, Chen S, Pollack R. Integration, loss, and reacquisition of defective viral DNA in SV40-transformed mouse cell lines. Virology 1983; 126:413-28.
113. Pollack R, Lo A, Steinberg B, Smith K, Shure H, Blanck G, et al. SV40 and cellular gene expression in the maintenance of the tumorigenic syndrome. Cold Spring Harb Symp Quant Biol 1980; 44 Pt 1:681-8.

RESEARCH GRANT SUPPORT

1. Principal Investigator; Biomedical Research Support Grant, Structure and function of the multigenic HLA class II region. $10,000; 10/1/90-3/31/91.

2. Principal Investigator; Research and Creative Scholarship Grant Award (University of South Florida), Major histocompatibility expression in human thyroid cells. $7120; 4/1/91-3/31/92.

3. Principal Investigator; American Cancer Society-Florida Division, Structure and function of the multigenic HLA class II region. $20,000; 6/1/91-5/31/92.

4. Principal Investigator; National Multiple Sclerosis Society, Functions of the multigenic HLA class II chromosome segment. $244,968; 10/1/91-9/30/94.

5. Principal Investigator; H. Lee Moffit Cancer Center Grant Program, Microscopic analysis of MHC chromatin. $41,553; 8/1/91-12/31/93.

6. Principal Investigator; American Heart Association, Retinoblastoma protein regulation of HLA class II gene expression. $130,020; 7/1/94-6/30/97.

7. Principal Investigator; Research and Creative Scholarship Grant Award (University of South Florida), Retinoblastoma protein regulation of invariant chain expression. $7500; 5/1/94-4/30/95.

8. Sponsor; American Society of Biochemistry and Molecular Biology High School Teacher Fellowship; $5500; 6/94-8/94.

9. Principal Investigator; American Lung Association, Florida Division, CIITA defects in non-small cell lung carcinoma. $49,912, 7/1/96-6/30/97.

10. Principal Investigator; American Heart Association, Florida Division, A novel defect in HLA class II gene expression. $99,395, 7/1/96-6/30/98.

11. Principal Investigator; Equipment cost-sharing funds, University of South Florida. $16,000, 7/1/96-6/30/98.

12. Principal Investigator, American Heart Association, Florida Division (declined due to

overlap with another awarded grant).

13. Principal Investigator, American Cancer Society, IRF-1 regulation of CIITA, $ 355,000, 7/1/98-6/30/01.

14. Principal Investigator, National Institutes of Health, Interferon regulatory factor 2 functions, 737,676, 4/99 - 3/04.

15. Principal Invesitgator, National Institutes of Health, Equipment Supplement to NIH grant, $10,855, 2001.

16. Principal Invesitgator, National Institutes of Health, supplement to NIH grant, $15,000, 2002.

17. BioStat International, Inc. Seminar Program gift (Maureen Lyden, President), $6000, 2006-07.

18. Principal Investigator, Negative regulation of MHC class II promoters, Florida Biomedical Society Bankhead-Coley Program, $179,000, 2007.

19. Principal Investigator, Interferon-gamma responses of stem cells, USF Internal Award Program, $5000, 2007.

20. Principal Investigator (Dr. William Sexton, co-PI). Cytoskeletal proteins in bladder cancer, $50,000, 2014-15.

21. 2017-20, Mentor, Student RISE fellowships, Morsani College of Medicine; other medical student, year-long, research stipend.

22. 2019, Mentor, external student fellowship, Saif Zaman, Med3.

MEETINGS/TALKS

1. G. Blanck, Y. Lu, G.D. Ussery, D. Marler, C. Pearson. American Cancer Society, Florida Division 17th Annual Research Seminar; Retinoblastoma protein regulation of HLA class II and CD74 expression in breast carcinoma cells (invited talk); March 5, 1994.

2. Y. Lu, G. Ussery, D. F. Marler, J. M. Boss, M. M. Muncaster, B. L. Gallie and G. Blanck. 14th Annual Florida Biochemist Meeting.. Retinoblastoma protein regulation of HLA class II and CD74 expression in breast carcinoma cells (invited talk).

3. Y. Lu, D. Marler and G. Blanck. American Society for Biochemistry and Molecular Biology Meeting Annual Meeting; Retinoblastoma protein regulation of HLA class II and CD74 expression in breast carcinoma cells; May, 1994.

4. G. Blanck, Y. Lu, M. Tschickardt, H. Xu, and B. Mach. American Cancer Society, Florida Division; Retinoblastoma protein regulation of HLA class II gene expression (invited talk); March 25, 1995.

5. G. Blanck, Y. Lu, D. Marler and H. Xu. Epigenetic regulation of transcription (Keystone Meeting); Retinoblastoma protein regulation of HLA class II gene expression; April 4-10, 1995.

6. G. Blanck, Y. Lu, D. Marler and H. Xu. FASEB-AII Meeting; Retinoblastoma protein regulation of HLA class II gene expression (invited talk); April 9-13, 1995.

7. G. Blanck, et al. International Congress of Immunology; Retinoblastoma protein regulation of HLA class II gene expression (invited talk); July 23-29, 1995. (invited talk) (Did not attend due to scheduling conflict).

8. G. Blanck, Y. Lu, B. Schmidt, M. Tschickardt, D. Berry. American Cancer Society, Florida Division; CIITA defects are common in human tumor lines and prevent rescue of HLA class II inducibility by retinoblastoma protein; March 30, 1996 (invited talk).

9. D. Berry, Y. Lu, B. Schmidt, P. Fallon, C. O'Connell, S-X. Hu, H-J. Xu and G. Blanck. FASEB-AAI Meeting; Retinoblastoma protein inhibits IFN-γ induced apoptosis. June 2-6, 1996.

10. Y. Lu, J. Boss, S-X. Hu, H-J. Xu and G. Blanck. FASEB-AAI Meeting; Apoptosis independent, retinoblastoma protein rescue of HLA class II mRNA IFN-γ inducibility in non-small cell lung carcinoma: Lack of surface class II expression associated with a specific defect in HLA-DR induction...June 2-6, 1996.

11. G. Blanck, Y. Lu, D. Berry, M. Tschickardt, B. Schmidt. FASEB-AAI Meeting: A defect in IFN-γ induction of CIITA, a common defect in human tumor lines, prevents retinoblastoma protein rescue of HLA class II inducibility...June 2-6, 1996.

12. Y. Lu, B. Schmidt, M. Tschickardt, D. Berry and G. Blanck. 12th International Histocompatibility Conference; CIITA defects in human tumor lines. June 9-12, 1996.

13. Y. Lu, J. Boss, S-X. Hu, H-J. Xu and G. Blanck. 12th International Histocompatibility Conference; Retinoblastoma protein rescue of HLA class II mRNA IFN-γinducibility in non-small cell lung carcinoma cells. June 9-12, 1996.

14. G. Blanck, D. Berry, Y. Lu, H-J. Xu. Cellular Immunology and the Immunotherapy of Cancer. February 1-7, 1997.

15. H.Xi., D.Berry, G.Blanck. Interferon regulatory factor-2 activation of the Type IV CIITA promoter. American Society for Biochemistry and Molecular Biology Meeting, May 16-20, 1998, Washington, D.C.

16. H.Zhang, A.Shepherd, G.Blanck. De-repression of HLA-DRA by hyperphosphorylation of Oct-1 protein in cells expressing retinoblastoma protein. Experimental Biology Meeting, April 27-21, 1999. Washington, D.C.

17. G. Blanck, H. Xi, H. Zhang, S. Wei, J. Djeu. Tumor suppressor proteins required for HLA class II and interleukin-8 expression. Cancer Immunosurveillance Meeting, October 4-6, 1999, New York City, NY.

18. G. Blanck, H.Xi, H.Zhang, S.Wei, J.Djeu. Tumor suppressor proteins required for HLA class II and IL-8 expression. Cellular immunology and immunotherapy of can cer, January 21-27, 2000, Sante Fe, New Mexico.

19. George Blanck, Harry Zhang, Jiazhi Sun, Sheng Wei, and Julie Djeu. Role of Interleukin-8 secretion in the effect of Retinoblastoma protein (Rb)-expression on tumorigenicity. American association of immunologists, May 12-16, 2000, Seattle, Washington.

20. Aaron Osborne, Hongquan Zhang, Wen-Ming Yang, Edward Seto, and George Blanck. Histone deacetylase activity represses IFN- inducible HLA-DR gene expression following the establishment of an open promoter chromatin conformation. Class II MHC gene control and disease relevance, March 22-25, 2001, Seabrook Island, South Carolina **(Invited talk)**.

21. Aaron Osborne, Hongquan Zhang, Wen-Ming Yang, Edward Seto, and George Blanck. Histone deacetylase activity represses IFN- inducible HLA-DR gene expression following the establishment of an open promoter chromatin conformation. Experimental Biology, 3/31-4/4/01, Orlando, Florida .

22. H. Zhang, S. Wei, J. Sun, D. Coppola, B. Zhong, G.D. Wu, B. Goodwin, S. Sebti, J.Y. Djeu and G. Blanck. Retinoblastoma protein activation of interleukin-8 expression inhibits tumor cell survival in nude mice. Experimental Biology, 3/31-4/4/01, Orlando, Florida .

23. B.L. Goodwin, H. Xi, D.D. Eason, N. Ghosh, K.L. Wright, U. Nagarajan, J.M. Boss and G. Blanck.Varying functions of specific MHC class II transactivator promoter III and IV elements in melanoma cell lines. Experimental Biology, 3/31-4/4/01, Orlando, Florida .

24. H. Xi, B. Goodwin, A.T. Shepherd and G. Blanck. IRF-2 regulation of CIITA *in vitro* and in mice. Experimental Biology, 3/31-4/4/01, Orlando, Florida .

25. H. Xi, B. Goodwin, A.T. Shepherd and G. Blanck. IRF-2 regulation of CIITA *in vitro* and in mice. Experimental Biology, 3/31-4/4/01, Orlando, Florida **(Invited talk)**.

26. D.D.Eason and G. Blanck. Threshold-dependent regulation of interferon signaling. Experimental Biology, 3/31-4/4/01, Orlando, Florida.

27. G. Blanck. Linking cell cycle regulation to the anti-tumor immune response: Molecular basis for the regulation of the HLA class II genes in tumor cells. USF Molecular Medicine series, 10/17/02 **(Invited talk) (cancelled)**.

28. G. Blanck. Linking cell cycle regulation to the anti-tumor immune response: Molecular basis for the regulation of the HLA class II genes in tumor cells. Research in Progress, Moffitt Cancer Center, 10/02 **(Invited talk)**.

29. G. Blanck. Transcription of methylated DNA mediated by a sequence specific DNA binding protein: RFX. University College, London, 7/15/2005 **(Invited talk)**.

30. G. Blanck. Transcription of methylated DNA mediated by a sequence specific DNA binding protein: RFX. Boston University, 12/8/2005 **(Invited talk)**.

31. G. Blanck. Transcription of methylated DNA mediated by a sequence specific DNA binding protein: RFX. Children's Research Institute, St. Petersburg FL, 12/16/2005 **(Invited talk)**.

32. G.Blanck. Disease mechanisms of MHC class II repression: Application of a promoter network paradigm. Moffitt Cancer Center, 11/2/2007 **(invited talk)**.

33. G.Blanck. Cancer Karyotype Genomics: What is it and how might it be relevant to tumor immunology. Moffitt Cancer Center, 10/9/2008 **(invited talk)**.

34. G.Blanck. Regulation of interlocking cancer GRN subcircuits by a small molecule inhibitor of Rb phosphorylation: Linking cell cycle regulation to tumor immunology. Moffitt Cancer Center, 11/18/2010

35. G.Blanck.Small molecule activation of MHC class II expression in tumor cells: The guidance of gene regulatory network subcircuits linking Rb to MHC class II. Texas A&M Health Sciences Center, 11/17/2011.

36. G. Blanck, T-cell receptor-β V and J usage, in combination with particular. HLA class I alleles, correlates with cancer survival patterns. AIRR meeting, Dec, 2017.

37. G. Blanck, Novel software pipelines for linking TIL CDR3s and cancer mutant amino acids, Tumor biology program, Moffitt Cancer Center (**invited talk**).

38. G. Blanck, several Moffitt Cancer Center and Molecular Medicine seminars, 2020.

Ph.D. THESIS STUDENTS

1. Yanmei Lu, Department of Biochemistry and Molecular Biology, USF College of Medicine. (served as a postdoctoral fellow at Genentech, South San Francisco; employed at Rigel Pharmaceuticals, South San Francisco; currently employed at Genentech, South San Francisco)

2. Donna Eason (formerly Berry), Department of Biochemistry and Molecular Biology, USF College of Medicine (graduated 6/00; current postdoctoral fellowship with Dr. Gary Litman, USF All Childrens' Hospital).

3. Aaron Osborne, Department of Biochemistry and Molecular Biology and Institute for Biomolecular Science, USF College of Medicine (graduated 6/01; subsequent VFW postdoctoral fellowship, Blanck Lab; currently USF COM student)

4. Hongkang (Ken) Xi, Department of Biochemistry and Molecular Biology, USF College of Medicine (graduated 12/00; formerly a postdoctoral fellow, Emory University, Atlanta; currently employed at Genentech).

5. Hongquan (Harry) Zhang, Department of Pathology, USF College of Medicine (graduated 11/01; currently a resident in Pathology, Wayne State University, Detroit; currently employed at Oakwood Healthcare system, Michigan).

DEPARTMENTAL GRADUATE COORDINATOR (2003-2005)

Establish and maintain course, dissertation-related, and other degree requirements; design and oversee written and oral qualifying exams; advise and participate in other ways in College of Medicine multidisciplinary doctoral program (separate from the departmental doctoral program); chair the departmental doctoral student admissions committee.

CLASSROOM TEACHING (1990-present)

Extensive classroom lecturing, discussion, and course director experience for USF College of Medicine medical and graduate student courses: medical molecular biology, biochemistry, and genetics courses; and doctoral program molecular biology, biochemistry and genetics courses; data management course; college of public health course; evidence based medicine course; advanced gene regulation technologies course; extensive undergraduate teaching in a small class setting; extensive experience as course director with very large class sizes, both brick and mortar and online.

Lecture topics: Complexity of the genome, Human genome project, Gene structure and transcription, Transcriptional regulation, Epigenetics, DNA repair and recombination, Chromatin structure, DNA microarrays, Cancer microarrays and proteomics, Chromosome biology, Recombinant DNA technology, Basic adaptive and innate immunity, T-cell activation, Antigen processing and presentation, Purine and pyrimidine metabolism, Signal transduction, Oncogenes and tumor suppressor genes, Apoptosis, DNA replication; Data management; Genomics; The cancer genome atlas; Genetics of metabolic disorders, hematologic disorders, musculoskeletal disorders, neurological disorders, cardiopulmonary disorders, renal disorders; Genetics of sexual development; Immunogenomics; big data and cybersecurity.

UNIVERSITY AND PROFESSIONAL SERVICE

1. Molecular Biologist Search Committee, Department of Biology; Gregory Stewart, Ph.D., Chairman; 1991 (Position frozen).

2. Molecular Biology Planning and Advisory Group, Department of Biochemistry and Molecular Biology, Lee Adair, Ph.D., Chairman; 1991.

3. Institute for Biomolecular Science Seminar Program: Transcription Control; Dave Dunnigan, Ph.D., Chairman (Department of Biology); 1991.

4. Retreat Organizer for the Institute for Biomolecular Science (IBS) Retreat, 9/27/91-9/29/91; Daniel Lim, Ph.D., Director of IBS; 1991.

5. Grant reviewer, Department of Veterans Affairs, Veteran's Administration (Washington D.C. 20420). Career Development Program; Richard J. Greene, M.D. Ph.D., Assistant Chief Medical Director for Research and Development; 1991.

6. Reviewer, *Journal of Biological Chemistry*, 1992, 2005.

7. Committee on Academic Status, University of South Florida College of Medicine; Marvin Dunn, M.D., Dean; 1992-94.

8. University Lecture Series Committee, University of South Florida; Barbara R. Sherman,

Interim Vice President for Student Affairs; 1992-94.

9. Comprehensive Qualifying Exam Committee, Department of Medical Microbiology and. Imunnology, USF College of Medicine, Jin Hong Liu, 1993.

10. Department Facilities and Equipment Committee, Department of Biochemistry and Molecular Biology, R. Kennedy Keller, Ph.D. Chairman; 1993.

11. Contact person, Wellcome Visiting Professor Jack. L. Strominger, 1994; USF College of Medicine, Marvin Dunn, M.D., Dean.

12. Contact person, USF Lecture Series lecturer Robert Pollack, 1994; USF, Laurie Woodward, Committee Chairperson.

13. Organizer, Molecular Immunology Seminar Series, 1995; Institute for Biomolecular Sciences, USF, Mary Jane Saunders, Ph.D., Director.

14. Grant reviewer, Department of Veterans Affairs, Veteran's Administration (Livermore, California). VA Merit Review Program; Werner T. Schlapfer, Ph.D., Chief, Offic or External Reviews, VA Merit Review Board, 1995.

15. Reviewer, *Journal of Immunology*, 1993-05.

16. Committee on Academic Status, University of South Florida College of Medicine; Marvin Dunn, M.D., Dean; 1995-7.

17. Faculty Council, University of South Florida College of Medicine, 1995-96 .

18. Organizer, Biochemistry and Molecular Biology Departmental Retreat; October 5-7, 1995.

19. Faculty Senate, University of South Florida, 1996-99.

20. Organizer, Biochemistry and Molecular Biology Departmental Retreat; September 30, 1996.

21. Director, Departmental Admissions Committee, 1997, 1998.

22. American Heart Association, Florida Affiliate Study Section, 1997.

23. Committee on Committees, USF College of Medicine, 1997.

24. American Heart Association Study Section, Southeastern Consortium, Columbus Ohio, 1999.

25. Grant reviewer, American Cancer Society (National), Ad hoc reviewer, 1999.

26. USF COM Faculty Council, 1999-03.

27. LCME Graduate Basic Science Education Committee, 1997-98.

28. USF COM Space committee, 1997-99.

29. Adviser, First year medical students, 1996-99.

30. Judge, Science Fair, Academy of the Holy Names, Tampa, Florida, 2000, 2002.

31. American Heart Association Study Section, Southeastern Consortium, Atlanta, Georgia, 2000.

32. Reviewer, *Journal of Cellular Biochemistry*, 2000-2002.

33. Committee on Medical Student Affairs, USF College of Medicine, 2000-2002.

34. Committee Bylaws Committee, USF College of Medicine, 2000-2002.

35. USF College of Medicine Research Committee, 2001-03.

36. Grant reviewer, Veterans Affairs Merit Grant Program, 2001.

37. Reviewer, *Cancer Research*, 2001.

38. Grant reviewer, Treadwell Foundation, 2001, 2005.

39. Reviewer, *Human Immunology*, 2001

40. Reviewer, *Molecular and Cellular Biology*, 2001-03.

41. Invited lecturer, USF College of Public Health, 2002-05.

42. Reviewer, *Journal of Cell Science*, 2002-03

43. Chair, Departmental APT committee, USF College of Medicine, 2003, 2006.

44. Chair, COM Research Subcommittee for raising funds for a seminar series, 2002-03

45. Chair COM Research Subcommittee for establishing parameters to evaluate the research vitality at the USF COM, 2003.

46. Grant reviewer, USF COM pilot grant program, 2003.

47. Graduate Coordinator, USF COM Department of Biochemistry and Molecular Biology, 2003-2005

48. Reviewer, *European Journal of Biochemistry*, 2003.

49. Reviewer, Extra-mural APT committees, 2003.

50. Reviewer, *Blood*, 2003.

51. Grant reviewer, All Childrens Hospital grant program, 2004.

52. Grant reviewer, USF internal awards program, 2004.

53. Retreat Organizer, USF COM Dept. of Molecular Medicine (formerly Biochemistry), 2003-05.

54. Seminar series organizer, USF COM Dept. of Molecular Medicine (formerly Biochemistry), 2003-07.

55. Editor, *Frontiers in Bioscience: Tumor cell regulation of the immune system*, 2004-05.

56. Grant reviewer, *The Wellcome Trust*, 2005.

57. Reviewer, *Leukemia, Febs Letters, and J. Biol. Chem.,* 2005

58. USF College of Medicine LCME committee, 2006.

59. USF Department Molecular Medicine APT committee, 2006-8.

60. Reviewer, *Oncogene*, 2006.

61. Reviewer, *Cancer Immunology Immunotherapy*, 2006

62. Executive Committee, Signature Program for Allergy and Immunology, USF Health, 2006-07

63. Reviewer, *Nucleic Acids Research,* 2008

64. Reviewer, *Cancer Immunology Immunotherapy*, 2008

65. Chair, USF College of Medicine Committee on Research

66. Member, USF Research Council, 2009-2011

67. Member, USF IRB, 2010-present

68. Reviewer, *Vaccine*, 2011-2014

69. Reviewer, *Heartjournal*, 2013

70. Reviewer, *Cytokine, Circulation, Gene, Genes and Immunity*, 2014

71. Reviewer, *Cancer informatics, Cell Cycle, Cell and Tissue Research, Circulation, Cytokine, Gene, Immunology Letters, Vaccine, Tumor biology,* 2015

72. Mentor, High School Science Fair projects, 2015

73. Member, Scientific Advisory Board, University of Dublin, Ireland, Chair: Günther Eissner, 2015.

74. Extensive reference letter contributions, msp3 program, Morsani College of Medicine; 2012-19.

75. USF-Moffitt transplant fellowship committee (Brian Betts, M.D., chair); 2015-16

76. Mentor high school science project (Kendal Clark, student, South Sumter High School; Emily Keeler, guidance counselor;); 2014-2016.

77. Grant reviewer, Cancer research UK, 2018.

78. Reviewer, *BBA, Genomics, Cancer Cell International, Gene, Bioinformatics, Cytokine, Cancer Genetics, Tumor Biology, Analytical Biochemistry, Immunology Letters, Gene Therapy, International Journal of Molecular Medicine, European Journal of Hematology, IEEE, BMC Cancer, Oncology Letters, Laboratory Investigation, Human Vaccines and Immunotherapy, Molecular Medicine Reports, Molecular and Clinical Oncology, Circulation, Oncotargets, and Dovepress*, 2016-2020.

79. Associated Editor *GENE (2017-2020), Cancer Cell International (2017-2019).*

80. Faculty Council, Morsani College of Medicine, 2016-2018.

81. USF technology committee, 2018-2020.

82. Mentor, high school science project (Raelynn Moses, Sumter High School, 2018-19).

83. Member, Adapative Immune Receptor Repository working group, subdivision of The Antibody Society, 2018-2020.

DISSERTATION COMMITTEES

1. Chang Liu, Department of Microbiology and Immunology, USF College of Medicine; Dr. Stephen Specter, major professor.

2. Szu-Hao Kung, Department of Microbiology and Immunology, USF College of Medicine; Dr. Peter Medveczky, major professor (graduated).

3. Michele Anderson, Department of Biochemistry and Molecular Biology, USF College of Medicine; Dr. Gary Litman, major professor (graduated).

4. Susan Hoffman, Department of Medical Microbiology and Immunology, USF College of Medicine; Dr. Kay Blanchard, major professor.

5. Gary Hellerman, Department of Biochemistry and Molecular Biology, USF College of Medicine; Dr. Larry Solomonson, major professor (graduated).

6. P.K. Burnette, Department of Medical Microbiology and Immunology, USF College of Medicine; Dr. Julie Djeu, major professor (graduated 1995).

7. Jin Hong Liu, Department of Microbiology and Immunology, USF College of Medicine; Dr. Julie Djeu, major professor (graduated 1994).

8. Hana Dawson, Department of Biochemistry and Molecular Biology, USF college of Medicine; Dr. Andrew Cannons, major professor (graduated 1996).

9. Terri Bowers, Department of Microbiology and Immunology, USF College of Medicine; Dr. Bert Anderson, major professor (graduated 1998).

10. Susan Dovhey, Department of Microbiology and Immnunology, USF College of Medicine; Dr. Hua Yu, major professor.

11. Nalanjahan Ghosh, Department of Biochemistry and Molecular Biology, USF College of Medicine, Dr. Ken Wright, major professor.

12. Ian Zhang, Institute for Biomolecular Studies, USF, Dr. Rich Jove, major professor.

13. Vashti Lacaile, Department of Biochemistry and Molecular Biology, USF College of Medicine, Dr. M. Adrolewicz, major professor.

14. Kevin Abrams, Department of Biology, USF, Dr. Melissa Rogers, major professor.

15. Zhen Shi, Department of Biochemistry and Molecular Biology, USF College of Medicine, Dr. Glorida Ferriera, major professor.

16. Mark Meads, Department of Microbiology and Immunology, USF College of Medicine, Dr. Peter Medveczey, major professor.

17. Ildiko Gyogy, Department of Biochemistry, USF COM, Dr. Ken Wright, major professor.

18. Bill Lagor, Department of Biochemistry, USF COM, Dr. Gene Ness, major professor.

19. Carisa Davis, Department of Biochemistry, USF COM, Dr. Andrew Cannons, major professor.

20. Wei Fu, Department of Pathology, Dr. Wenlong Bai, major professor

21. Sungman Park, Department of Pathology, Dr. Jin Cheng, major professor.

22. Nadine Bewry, Department of Medical Microbiology and Immunology, Dr. Lori Hazelhurst, major professor.

23. Tracy Sherwood, Department Molecular Medicine, Dr. Thomas Klein, major professor.

24. Shara Pantry, Department Molecular Medicine, Dr. Peter Medveczky, major professor.

25. David Woods, Department of Molecular Medicine, Dr. Eduardo Sotomayor, major professor.

26. Jillian Whelan, Department of Molecular Medicine, Dr. Michael Teng, major professor.

27. Robert Vander Velde, Department of Molecular Medicine (current)

28. Aya Elmarsafawi, Department of Molecular Medicine (current)

UNDERGRADUATE and GRADUATE THESIS STUDENTS; other research students

1. Marc Kaprow, 1991.
2. Nirav Shah, 1993.
3. Michael Tschickardt, 1994 . (USF College of Medicine)
4. Brian Schmidt, 1996. (Toledo Medical College)
5. Stacy Carter, 1997. (Toledo Graduate School)
6. Alex Sheppard, 1998. (USF College of Medicine)
7. Kim Edmonson, 1998. (Nova College of Osteopathy)
8. Romeena Tejiram, 2001 (USF College of Public Health)
9. Kristy Kazemfar, 2001 (UF, technician)
10. Elizabeth Le, 2001 (USF College of Medicine; Daytona Halifax Medical Center)
11. Cassandra Wright (inactive)
12. Kimberly Palubin, 2003 (Emory Medical School)
13. Swetha Narsing, 2008, USF bioinformatics master's program intern
14. Libia Pava, 2012, undergraduate (New York Medical College)
15. Jacob Berger, 2012, undergraduate (dental school)
16. Kevin Cronin, 2012, master's student (UF College of Medicine)
17. Shea Ford, 2013, master's student (UF College of Medicine)
18. Mark Frangione, 2013, master's student
19. Michele Parry, 2014-15, master's student (FIU College of Medicine)
20. Mohammad Samy, 2014- , undergraduate
21. Shanitra Butler, 2014-15, master's intern (USF Clinical research coordinator)
22. James A. Mauro, 2012-16, medical student (interviewing for residencies)
23. Francesca Blazekovic, 2013-2015, master's student (Ross College of Medicine)
24. Marlene Garcia, 2014-15, master's student (Ross College of Medicine)
25. John Yavorski, Yaping Tu, Jay Patel, Andrea Roca, Blake Callahan, Rebecca Stoll,

Diana Fisler, Daniel Segarra, Etienne Gozlan, master's students, 2016-2020.

26. Wie Lue Tong, Anne Mai, Jacob Kinskey, Shayan Falasiri, Dhiraj Sikaria, Saif Zaman, Boris Chobrutskiy, Karisa Sereneau, Andrea Diviney, Juan Arturo, Jay Patel, Michelle Yeagley, Monica Hsiang, Taha Huda, medical students, 2015-2020.

27. Tasnif Rahman, undergraduate honors student, 2018.

28. Michael Diaz, undergraduate honors student, 2020.

HONORS

1. Election to regular membership, American Society for Biochemistry and Molecular Biology; 1991.

2. Election to regular membership, American Association of Immunologists; 1992.

3. Election to Graduate Student Advisor, Graduate Medical Sciences Program, USF College of Medicine, 1993.

4. Election to regular membership, American Association for Cancer Research, 1996.

5. Inducted into Robert Good Honor Society, Morsani College of Medicine, USF, 2019.